BETHESDA, Md., February 20, 2008 /PRNewswire-FirstCall/ --
Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") today
announced the most recent long-term follow-up data, as of year-end
2007, on disease progression and overall survival in patients
taking part in its Phase I and Phase I/II clinical trials for newly
diagnosed patients with Glioblastoma multiforme ("GBM"), the most
aggressive form of brain cancer. The additional data covers the
period from April 2007 through year-end 2007. During this time,
none of the patients experienced disease progression (recurrence)
and only one patient died (at 36.4 months). Thus, the data show
that in the 19 clinical trial patients receiving DCVax(R)-Brain in
addition to Standard of Care, both the median overall survival and
the median time to disease progression (recurrence) are more than
twice as long as in patients receiving the Standard of Care for
GBM. Dr. Linda Liau, Associate Professor of Neurosurgery and
Director of the Malignant Brain Tumor Program at the UCLA School of
Medicine ("UCLA"), served as the Principal Investigator for the
trial.

Since 2005, the Standard of Care for patients with GBM is
surgery followed by a combination of radiation and daily Temodar(R)
chemotherapy, and then 6 monthly cycles of Temodar chemotherapy.
The studies defining this Standard of Care achieved a median time
to progression of 6.9 months and a median overall survival of 14.6
months (Stupp, et. al., N Engl J Med, 352:987, 2005). Further data
from UCLA have demonstrated a somewhat longer median time to
progression of 8.1 months and median overall survival of 17.0
months in patients with GBM who received Standard of Care.

The year-end 2007 data obtained by the Company concerning the 19
patients from the two trials at UCLA with newly diagnosed GBM
continue to be positive, with no patients progressing and only one
patient dying (at 36.4 months). Overall, the long-term follow-up
data are now as follows:

o 8 of 19 patients are still alive (ranging from 24.5 months to 92
months), with median overall survival in all patients of 33.8 months
(p < 0.0079) (the "p value" measures the likelihood that the observed
clinical effect is due to chance: a 'p' value of 0.0079 means that
there is a less than 1% possibility that the longer survival time of
DCVax(R)-Brain-treated patients is due to chance);
o 5 of the 8 patients who are still alive show no signs of cancer
recurrence, with follow-up time ranging from 41 months to 92 months;
o The median time to progression (i.e. tumor recurrence) is 18.1 months,
compared to 8.1 months for patients treated at UCLA during the same
time period (p = 0.00001);
o 90% of patients have surpassed the Standard of Care median time to
progression of 8.1 months;
o 84% of patients have surpassed the Standard of Care median overall
survival time of 17.0 months;
o To date, 68% of patients receiving DCVax(R)-Brain in addition to
Standard of Care have lived longer than 2 years, 42% have lived longer
than 3 years, and 26% have lived longer than 4 years (48, 54, 57, 62
and 92 months so far);

"Findings such as these, where we are seeing 68% of our
DCVax(R)-Brain-treated patients with GBM alive after two years, and
26% alive for more than 4 years (and counting) reinforce our belief
that DCVax(R)-Brain may make a significant difference in the lives
of patients with GBM," stated Dr. Alton L. Boynton, President and
Chief Executive Officer of Northwest Biotherapeutics. "We believe
that the results to date are particularly striking, and we plan to
give patients continued booster injections at 3 month intervals. We
believe that these booster injections will further enhance and
sustain the patient's immune response in attacking the cancer and
preventing or delaying its recurrence."

GBM, the most aggressive form of brain cancer, is estimated to
have caused over 12,000 deaths in the US in 2007; and brain cancer
is estimated to have caused over 39,000 deaths in Europe in 2002
(in each case the last year for which estimates are available).
Beyond surgery to remove the brain tumor, and radiation therapy,
there are only two treatments for GBM currently approved by the
Food and Drug Administration ("FDA"). Those treatments have been
shown in clinical trials to add only 10-12 weeks of survival in GBM
patients. In contrast, in the two clinical trials conducted at UCLA
with DCVax(R)-Brain, the patients have experienced much longer
extensions of the time to disease progression (recurrence) and
overall survival.

DCVax(R)-Brain is a type of personalized immunotherapy designed
to stimulate a patient's own immune system to fight cancer.
DCVax(R)-Brain is made up of the patient's own dendritic cells that
have been "educated" to recognize and destroy cancer cells bearing
the biomarkers of the patient's tumor. Each patient undergoes tumor
removal through surgery as part of the current Standard of Care.
Dendritic cells drawn from a sample of the patient's blood are
exposed in a lab dish to the biomarkers of the patient's own tumor,
and are thereby activated and "educated." These activated and
"educated" dendritic cells are injected back into the patient, in a
simple small injection under the skin similar to a flu shot or
insulin shot, at a series of time points several weeks apart and
then months apart. These dendritic cells are then able to mobilize
the immune system to recognize and attack the cancer, and do so
without toxicity to the patient (i.e., without grade 3 or 4 adverse
events)

The Company has initiated a large Phase II clinical trial of
DCVax(R)-Brain that is designed and powered to serve as a pivotal
trial in support of potential product registration. The trial is
currently screening and enrolling patients at a number of sites
across the U.S.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on
developing immunotherapy products that treat cancers more
effectively than current treatments, without toxicity, on a
cost-effective basis. The Company has two broad platform
technologies: dendritic cell-based vaccines and therapeutic
antibodies. The Company is currently conducting a large Phase II
clinical trial in GBM, which is designed and powered to serve as a
pivotal trial. The Company has also received clearance from the FDA
for a large Phase III trial in prostate cancer, and clearance from
the FDA for Phase I trials in five other cancers. The Company has
started, and is currently enrolling patients in, a Phase I/II trial
with DCVax(R) for recurrent ovarian cancer. The Company's second
technology platform, involving antibodies to CXCR4, is at the late
pre-clinical development stage.

Statements made in this news release that are not historical
facts, including statements concerning future treatment of patients
with GBM using DCVax(R)-Brain and future clinical trials, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as "expects,"
"believes," "intends," and similar expressions are intended to
identify forward-looking statements. Actual results may differ
materially from those projected in any forward-looking statement.
Specifically, there are a number of important factors that could
cause actual results to differ materially from those anticipated,
such as the Company's ability to raise additional capital, risks
related to the Company's ability to enroll patients in its clinical
trials and complete the trials on a timely basis, the uncertainty
of the clinical trials process, uncertainties about the timely
performance of third parties, and whether the Company's products
will demonstrate safety and efficacy. Additional information on
these and other factors, which could affect the Company's results,
is included in its Securities and Exchange Commission ("SEC")
filings and the Risk Factors section of the Form S-1 recently filed
by the Company. Finally, there may be other factors not mentioned
above or included in the Company's SEC filings or recently filed
Form S-1 that may cause actual results to differ materially from
those projected in any forward-looking statement. You should not
place undue reliance on any forward-looking statements. The Company
assumes no obligation to update any forward-looking statements as a
result of new information, future events or developments, except as
required by securities laws.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.